Quick Answer
Evofem Biosciences, Inc. reported Research And Development Expense of $1.85 million for the year ending 2024.
- Evofem Biosciences, Inc. showed a decrease of -37.2% in Research And Development Expense from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Research And Development Expense has declined by 83.9%.
- Historical annual values: Fiscal year 2024: $1.85 million | Fiscal year 2023: $2.94 million | Fiscal year 2022: $25.03 million | Fiscal year 2021: $33.13 million | Fiscal year 2020: $17.05 million | Fiscal year 2019: $22.23 million | Fiscal year 2018: $43.42 million | Fiscal year 2017: $23.54 million | Fiscal year 2016: $6.58 million | Fiscal year 2015: $34.41 million | Fiscal year 2014: $5.17 million | Fiscal year 2013: $11.45 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: